This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo® provides dosing options to treat paediatric patients from birth1

Dosage in paediatric patients with normal renal function (CrCL > 50 mL/min*)

Age and bodyweight

Dosage

Frequency

Infusion time (minutes)

Neonates from birth to <2 months†

6 mg/kg

Every 8 hours

60

2 months to <2 years

8 mg/kg

Every 8 hours

5-60†‡

2 years to <12 years

12 mg/kg up to 400 mg

Every 8 hours

5-60†‡

12 years to <18 years and bodyweight <33 kg

12 mg/kg up to 400 mg

Every 8 hours

5-60†‡

12 years to <18 years and bodyweight ≥33 kg

600 mg

Every 12 hours

5-60†‡

A high-dose regimen† is also available for paediatric patients aged ≥2 months with cSSTI confirmed or suspected to be caused by S. aureus with an MIC = 2 mg/L or 4 mg/L to Zinforo (refer to dosing tables within the SmPC for more detailed information).

Zinforo can be used in patients with varying degrees of renal impairment1

Dosage in children aged from 2 years to <12 years with CrCL ≤50 mL/min and adolescents aged from 12 to <18 years with bodyweight <33 kg and CrCL ≤50 mL/min

For high dose regimen recommendations for patients with renal impairment, refer to dosing tables within the SmPC.

Explore More

Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI1-4​​**

Learn more
*Calculated using the Schwartz formula for paediatric patients (in mL/min/1.73 m2). 1
¶Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.1
†Infusion times of <60 minutes, neonatal and high-dose recommendations are based on PK/PD analyses only.1 
‡ Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis).1 Infusion times of <60 minutes are based on PK/PD analyses only.1
** Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1 

​​​Abbreviations
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CrCL, creatinine clearance; MIC, minimum inhibitory concentration.
Reference
  1. ZINFORO. Summary of Product Characteristics
  2. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18 
  3. Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7 
  4. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
PP-ZFO-GBR-0136. June 2021

Discover further specific information on the use of Zinforo in neonates, infants and children here:

Zinforo provides simple dosing and a flexible infusion time for the majority of adult and adolescent patients1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No